Frontier Pharma - Rheumatoid Arthritis:
Identifying and Commercializing First-in-Class Innovation
A
new pharmaceutical report – “Frontier Pharma – Identifying and Commercializing
first-in-class Innovation”. This highly competitive market is saturated with
multiple targeted monoclonal Antibody (mAb) therapies and small molecules, yet
more of these treatments are expected to enter the market over the next few
years. Despite this, the current developmental pipeline is highly innovative
beyond these me-too products and incremental innovations and promises a number
of first-in-class products across all stages. These new developments are driven
by improvements in the understanding of signaling pathways and underlying
disease mechanisms of Rheumatoid Arthritis (RA).
To check out the complete table of
contents, visit:
http://www.marketresearchreports.biz/analysis-details/frontier-pharma-rheumatoid-arthritis-identifying-and-commercializing-first-in-class-innovation
These
highly innovative products are expected to increase the diversity of available
products, in terms of mechanism of action over the coming decade and are likely
to have a significant impact on the dynamics of the clinical and commercial
landscape. The market is also characterized by high activity in licensing and
co-development deals. In particular, there is sustained commercial interest in
pipeline biologic therapies with a range of molecular targets. There is also
considerable interest in small molecule inhibitors of intracellular kinases
despite their clinical performances not being as well established as biologics
or mAbs.
Scope
The
report analyzes the RA pipeline and strategic alliance landscape with
particular emphasis on first-in-class programs.
The
report provides:
- A brief introduction to RA, including symptoms, pathophysiology, and an overview of the pharmacotherapy
- Highlights of the changing molecular target landscape between marketed and pipeline products with particular focus on innovation
- A comprehensive review of first-in-class pipeline therapies; the pipeline is analyzed by Phase distribution, molecule type, molecular target, and administration route
- Identification and assessment of first-in-class molecular targets highlighting early-stage programs with clinical utility that has yet to be evaluated, as well as an in-depth literature review of novel molecular targets
- Assessment of the licensing and co-development deals for RA therapeutics
To buy the copy of this report, visit: http://www.marketresearchreports.biz/analysis/176667
Reasons
to Buy
The
report will assist business development strategies of companies who wish to
develop RA therapies with improved benefits to existing treatments. In
addition, this report will be of interest to companies seeking to expand
pipeline portfolios through licensing agreements and co-development deals
allowing them to:
- Understand the overall focal shifts in therapeutic molecular targets of RA treatments
- Identify first-in-class product development and understand the therapeutic and commercial prospects of first-in-class developmental programs based on available animal model data
- Assess the value of products benchmarked against licensed and co-developed therapeutic programs
- Spot first-in-class programs that are potentially available for licensing and co-development deals
Table
of Contents
1
Table of Contents 5
2
Introduction 9
3
Rheumatoid Arthritis 12
4
Overview of Pipeline Products for Rheumatoid Arthritis 24
5
Target and Pipeline Program Evaluation 38
6
Deals and Strategic Consolidations 74
7
Appendix 99
Latest Reports:
Enterprise
Video Market - Global Industry Analysis, Size, Share, Growth, Trends and
Forecast, 2013 - 2019: http://www.marketresearchreports.biz/analysis-details/enterprise-video-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019
The
rapid globalization has increased the need for effective communication systems.
Companies have been experiencing an escalating need of video interfaces for
communication purposes, owing to its ability to increase outreach and
productivity. Thus, enterprise video services are used on a large extent in
these areas. The market is segmented on the basis of hardware, such as video
recording and storage devices, video casting devices, video management and
control and video distribution. On the basis of software the market is
classified as, video content management, video analytics software, video
security software, video collaboration software, video asset management and
video encoding and decoding software.
Increasing
BYOD culture and adoption of cloud technologies are the key driving forces for
this market. Moreover, with the introduction of newer technologies, there has
been innovation in advanced video platforms. Moreover, enterprise video service
helps reduce overall capital expenditure and improves flexibility in remote
conditions. As a result, enterprise video market is expected to grow rapidly
over the forecast period.
Similarly,
on the basis of services market is segmented as consulting, system integration,
managed services and other services. Further, the market is also segmented on
the basis of delivery modes, such as web conferencing, video streaming,
webcasting and video conferencing. Moreover, the enterprise video market is
classified into different industry verticals which include banking and
financial services (BFSI), academia and government, consumer goods and retail,
media and entertainment, healthcare, manufacturing, transportation and
logistics, and telecom and IT. The market is further segmented on the basis of
applications, such as corporate communication, knowledge sharing and management
and learning and development among others.
Gonorrhea
Diagnostic Market - Global Industry Analysis, Size, Share, Growth, Trends and
Forecast, 2013 - 2019: http://www.marketresearchreports.biz/analysis-details/gonorrhea-diagnostic-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019
Gonorrhea
is a contagious sexually transmitted disease caused by the bacterium Neisseria
gonorrhoeae. The disease can also pass on to a new born through infected mother
during parturition. This disease can affect both men and women. The bacterium
grows in warm and moist areas of uterus, reproductive tract, fallopian tubes
and urethra. In addition, the bacterium can also grow in the throat, mouth and
anus. According to Center for Disease Control (CDC), in 2010 the total number
of people suffering from gonorrhea was estimated to be around 3 lacs in the
U.S.
Diagnostic
tests for gonorrhea include diagnostic imaging, flow cytometry, gel
microdroplets, chromatography, artificial intelligence, liposomes, Differential
Light Scattering (DLS), molecular diagnostics and monoclonal antibodies
test. Amongst these tests, molecular diagnostic is most preferred test.
Molecular test include Nucleic Acid Amplification Tests (NAAT) which is highly
sensitive test for urine and swab test. It is FDA approved for the diagnosis of
gonorrhea.
Change
in lifestyle has resulted in multiple sex and sex partner. It has been observed
that three out of five people suffer from chlamydia every year and it is
expected to rise drastically. It has been reported that in 2011, gonorrhea
increased by 61% globally. This severe growth of gonorrhea patients worldwide
would augment the growth of this market. Gonorrhea increases the risk of HIV
infection and this is raising serious concern amongst governments of various
nations. According to CDC, Federal Domestic Assistance grants a project under
section 318c. This project aimed for the development and implementation of
prevention and control program for this disease. This increasing concern
of government would trigger the growth of this market. In addition, rise in disposable
income of population would also increase the growth of this market.
About Us
MarketResearchReports.Biz is the most comprehensive
collection of market research reports. MarketResearchReports.Biz services are
specially designed to save time and money for our clients. We are a one stop
solution for all your research needs, our main offerings are syndicated
research reports, custom research, subscription access and consulting services.
We serve all sizes and types of companies spanning across various industries.
Contact
M/s
Sheela
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA
– Canada Toll Free: 866-997-4948
No comments:
Post a Comment